Redefining BASDAI cut-offs in axial spondyloarthritis: implications for patients' eligibility for treatment with biologic disease-modifying antirheumatic drugs

医学 巴斯代人 强直性脊柱炎 轴性脊柱炎 抗风湿药物 物理疗法 内科学 逻辑回归 痹症科 疾病严重程度 脊柱炎 子群分析 抗风湿药 疾病 成果研究 巴斯菲
作者
Stylianos Georgiadis,Lykke Midtbøll Ørnbjerg,Brigitte Michelsen,Tore K Kvien,Mehrdad Shoae Kazemi,Kristýna Bubová,Herman F. Mann,Karel Pavelká,Bente Glintborg,Anne Gitte Loft,Helena Santos,Andreas Reich,Anne C. Regierer,Jarno Rutanen,Laura Kuusalo,Gary John Macfarlane,Gareth Tudor Jones,Adrian Ciurea,Michael John Nissen,Björn Guðbjörnsson
出处
期刊:The Journal of Rheumatology [The Journal of Rheumatology Publishing Company Limited]
卷期号:: jrheum.2026-0445
标识
DOI:10.3899/jrheum.2026-0445
摘要

OBJECTIVE: To compare a newly proposed Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) cut-off for high disease activity (BASDAI≥2.5) with the corresponding Axial Spondyloarthritis Disease Activity Score (ASDAS) cut-off (ASDAS≥2.1) as an eligibility criterion for initiating a biologic disease-modifying antirheumatic drug (bDMARD) in routine care patients with axial spondyloarthritis (axSpA). METHODS: Real-world patients with axSpA initiating their first bDMARD from 9 European registries were analysed. Patients were categorised into 4 subgroups according to the fulfilment of ASDAS and BASDAI criteria at baseline, and treatment effect was assessed at 6 months using several response and remission outcomes. Adjusted logistic regression analyses were performed to determine whether fulfilling ASDAS and BASDAI criteria was associated with achieving the treatment outcomes. RESULTS: Of 6,329 patients included, 90.9% fulfilled both ASDAS and BASDAI eligibility criteria at baseline, 2.5% and 2.7% fulfilled either ASDAS or BASDAI criterion alone, while 3.8% fulfilled neither. The subgroup fulfilling both criteria demonstrated the highest responses at 6 months, while the highest remission outcomes were observed in the subgroup fulfilling neither criterion. Fulfilling either criterion at baseline was significantly associated with achieving response outcomes at 6 months, whereas a negative association was observed for remission outcomes. CONCLUSION: In a multinational European cohort, a very large overlap between the BASDAI and the ASDAS eligibility criteria was shown, and the predictive ability of the two criteria to achieve treatment outcomes was comparable. These findings support the use of BASDAI≥2.5 as a criterion for initiating bDMARD therapy in axSpA, particularly when ASDAS is unavailable.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
Czz发布了新的文献求助10
2秒前
2秒前
yl发布了新的文献求助10
2秒前
瘦瘦冬寒完成签到 ,获得积分10
2秒前
2秒前
XD完成签到 ,获得积分10
2秒前
Lucas的应助被壮观海云采纳,获得10
3秒前
栗清歌完成签到,获得积分10
5秒前
卤一碗芋头糕完成签到,获得积分10
5秒前
高兴凝安完成签到 ,获得积分10
5秒前
5秒前
舒适的秋尽完成签到 ,获得积分10
6秒前
学霸业的应助被yu123123采纳,获得10
6秒前
荼蘼发布了新的文献求助10
7秒前
追寻的觅双完成签到 ,获得积分10
7秒前
yuyu完成签到,获得积分10
8秒前
syvshc的应助被府中园马采纳,获得10
9秒前
9秒前
向阳而生完成签到,获得积分10
9秒前
ttttTTTT发布了新的文献求助10
10秒前
包容映安发布了新的文献求助10
10秒前
酷波er的应助被zzz采纳,获得10
11秒前
pyb0919完成签到,获得积分10
13秒前
13秒前
13秒前
小蘑菇的应助被温暖霸采纳,获得10
14秒前
沈格完成签到,获得积分10
14秒前
大模型的应助被xucc采纳,获得10
14秒前
15秒前
ggjun完成签到,获得积分10
15秒前
15秒前
荼蘼发布了新的文献求助10
16秒前
yu123123完成签到,获得积分10
16秒前
啦啦啦完成签到 ,获得积分10
16秒前
时衍发布了新的文献求助10
17秒前
HJJHJH发布了新的文献求助10
18秒前
18秒前
18秒前
辰的小猫发布了新的文献求助10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175262
求助须知:如何正确求助?哪些是违规求助? 9567017
关于积分的说明 21789663
捐赠科研通 7769695
什么是DOI,文献DOI怎么找? 3431840
关于科研通互助平台的介绍 2556124
邀请新用户注册赠送积分活动 2477241